Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Schering-Plough Corporation

http://www.schering-plough.com

Latest From Schering-Plough Corporation

US R&D Setbacks For Multiple Japanese Firms

Several Japanese firms are facing R&D challenges and setbacks in the US, in the form of missed Phase III endpoints, trial recruitment difficulties and a Complete Response Letter.

Research & Development Clinical Trials

US FDA’s June Approvals Forecast: Nearly 30 Goal Dates Suggest Hot Start To Summer

June goal dates include RSV and pneumococcal vaccines, two COPD therapies, Rocket and Sarepta gene therapies, and lots of oncology.

US FDA Performance Tracker Drug Review

Early Results Erode Belief In Biohaven’s Protein Degrader

Phase I results from BHV-1300 underwhelmed investors, but Biohaven is moving ahead and has many more shots on goal in protein degradation and beyond.

Clinical Trials Companies

Finance Watch: Investors Support Strategic Shifts At Cullinan, Cidara

Public Company Edition: Cullinan and Cidara shifted their strategic directions and found investors to bring along for the ride. Also, Intra-Cellular closed a post-Phase III $575m follow-on offering and Tarsus accessed up to $200m from Pharmakon.

Financing Growth
See All

Company Information

  • Other Names / Subsidiaries
    • Integrated Therapeutics Group
    • Nobilon International BV
    • Organon BioSciences
UsernamePublicRestriction

Register